For The Public (SE) For The Public (IT) For The Public (DE) For The Public (FI) For The Public (CZ) For The Public (GR)
Home
About Us
Contact us
Consortium Description
Management
Research Partners
Partner Institutions
Research Activities
Summary
Dissemination of Knowledge
News
Contact
Press Releases
Events
FP6 Facts
For The Public
(Multilingual Content)
Project
News And Views
FP6

Content : Dissemination of Knowledge
Posted on Friday, October 03 @ 12:27:33 EEST by admin
Research Activities
Eliopoulos AG: "Make and Brake" in Cell Signaling. Science 2008, 321: 648-649.
Moschonas A, Kouraki M, Knox PG, Thymiakou E, Kardassis D & Eliopoulos AG: CD40 Induces antigen transporter and immunoproteasome gene expression in carcinomas via the coordinated action of NF-kappaB and of NF-kappaB-mediated de novo synthesis of IRF-1. Mol. Cell. Biol. 2008, 28: 6208-6222.
Loskog A and Eliopoulos AG: CD40 Ligand-based Cancer Therapy. In: New Gene Therapy & Cancer Research, 2008, pp 1-7. Ed. WB Gustaffsson, Nova Publishing Group.
Bauerschmitz GJ, Kangasniemi L, Pesonen S, Eriksson M, Porten M, Herrmann I, Virkkunen P, Tarkkanen M, Ranki T, Hakkarainen T, Kanerva A, Rein D & Hemminki A. Tissue specific promoter controlled oncolytic adenoviruses for killing of CD44+CD24-/low breast cancer cells. Cancer Res. 2008; 68: 5533-9.
Sala G, Dituri F, Previdi S, Maffucci T, Mazzoletti M, Rossi C, Iezzi M, Lattanzio R, Piantelli M, Iacobelli S, Broggini M, Falasca M: Phospholipase C gamma1 is required for metastasis development and progression. Cancer Res. 2008; 68: 10187-10196.
Sarkioja M, Pesonen S, Raki M, Hakkarainen T, Salo J, Kanerva A & Hemminki A. Changing the adenovirus fiber for retaining gene delivery efficacy in the presence of neutralizing antibodies. Gene Ther. 2008;15: 921-9.
Krcova Z, Ehrmann J, Krejci V, Eliopoulos A, Kolar Z. Tpl-2/cot and cox-2 in breast cancer. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2008; 152: 21-5.
Sarkioja M, Eriksson M, Ristimäki A, Desmond RA, Hakkarainen T, Kanerva A, Hemminki A. The cyclo-oxygenase 2 promoter is induced in non-target cells following adenovirus infection, but an AU-rich 3' UTR destabilization element can increase specificity. J Gene Med. 2008; 10:744-53.
Raki M, Sarkioja M, Desmond RA, Chen D-T, Hemminki A and Kanerva A. Oncolytic adenovirus Ad5/3-?24 and chemotherapy for treatment of orthotopic ovarian cancer. Gynecol Oncol, 2008;108:166-72.
Ribacka C and Hemminki A. Virotherapy as an approach against cancer stem cells. Curr Gene Ther. 2008;8:88-96.
 
CD40, cancer, therapy, PI3 kinase, immunotherapy, gene therapy, signaling, European Commission Program, FP6, Virtual Medical Lab, Faculty of Medicine, University of Crete
 
 



Visitors:
Designed by: George Savakis for Virtual Medical Lab (Faculty of Medicine - Univercity of Crete)